Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Deals

Rainsure Scientific Secures Series C1 Funding for Digital PCR Development

Fineline Cube Nov 17, 2022

Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly...

Company Drug

CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication

Fineline Cube Nov 17, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...

Company Deals

Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion

Fineline Cube Nov 17, 2022

Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...

Company Drug

Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE

Fineline Cube Nov 17, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...

Company Drug

CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Nov 17, 2022

China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...

Company Deals

HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology

Fineline Cube Nov 17, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...

Company

Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development

Fineline Cube Nov 17, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...

Company

Novartis Considers Sale of Non-Core Units to Fund Innovation

Fineline Cube Nov 17, 2022

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...

Company Deals

Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series

Fineline Cube Nov 17, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into...

Company Drug

Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval

Fineline Cube Nov 17, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...

Company Deals

MicroTech Medical Plans IPO on Shanghai’s STAR Market

Fineline Cube Nov 17, 2022

China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct...

Drug

Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...

Company

Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award

Fineline Cube Nov 16, 2022

China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...

Company Deals

Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines

Fineline Cube Nov 16, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...

Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Company Drug

Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study

Fineline Cube Nov 16, 2022

China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...

Company Drug

Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631

Fineline Cube Nov 16, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...

Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Posts pagination

1 … 578 579 580 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.